Showing results (81-90 of 349) with videos related to
Sort By:
Pageof 35
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 23, 2005
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapyMelissa P Upton, Robert A Parker, Amanda Youmans, et al.Cancer Immunology, Immunotherapy : CII|February 22, 2019
Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinomaIzak Faiena, Stephanie H Astrow, David A Elashoff, et al.World Journal of Urology|May 13, 2018
Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapyIzak Faiena, Amirali Salmasi, Neil Mendhiratta, et al.World Journal of Urology|September 15, 2019
Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patientsJohannes Heide, Silvia Ribback, Tobias Klatte, et al.Urologic Oncology|May 21, 2020
Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort studyPatrick M Lec, Andrew T Lenis, Wayne Brisbane, et al.Thyroid : Official Journal of the American Thyroid Association|February 24, 2022
Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's ThyroiditisTina Mosaferi, Karen Tsai, Samantha Sovich, et al.Clinical Genitourinary Cancer|February 14, 2009
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinomaKathryn A Bylow, Michael B Atkins, Edwin M Posadas, et al.European Urology Focus|July 6, 2025
KIM-1 as a Prognostic Marker in Renal Cell CarcinomaClara Steiner, Marc Machaalani, Joseph V Bonventre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK TrialDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.Journal of the American College of Cardiology|September 5, 2015
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase InhibitorsWeijuan Li, Kevin Croce, David P Steensma, et al.Pageof 35